share_log

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $10

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $10

HC Wainwright & Co.維持對CASI Pharmicals的買入,將目標價下調至10美元
Benzinga Real-time News ·  2022/11/15 06:18

HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $12 to $10.

HC Wainwright & Co. 分析師肖恩·李維持CASI Pharmicals(納斯達克股票代碼:CASI)的買入,並將目標股價從12美元下調至10美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論